1. Inicio
  2. Publicaciones
  3. SENECA study: staging endometrial cancer based on molecular classification.

SENECA study: staging endometrial cancer based on molecular classification.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Chacon E
  • Boria F
  • Lyer RR
  • Fanfani F
  • Malzoni M
  • Bretová P
  • Luzarraga Aznar A
  • Fruscio R
  • Jedryka MA
  • Tóth R
  • Perrone AM
  • Kakkos A
  • Cristóbal Quevedo I
  • Congedo L
  • Zanagnolo V
  • Fernandez-Gonzalez S
  • Ferro B
  • Narducci F
  • Hovhannisyan T
  • Aksahin E
  • Cardenas L
  • Oliver MR
  • Nozaleda G
  • Misiek M
  • Ferrero A
  • Pain FA
  • Zarragoitia J
  • Diaz C
  • Ceppi L
  • Mehdiyev S
  • Roldán-Rivas F
  • Guijarro-Campillo AR
  • Amengual J
  • Manzour N
  • Sanchez Lorenzo L
  • Núñez-Córdoba JM
  • Gonzalez Martin A
  • Minguez JA
  • Chiva L
  • SENECA Working Group

Abstract

OBJECTIVE: Management of endometrial cancer is advancing, with accurate staging crucial for guiding treatment decisions. Understanding sentinel lymph node (SLN) involvement rates across molecular subgroups is essential. To evaluate SLN involvement in early-stage (International Federation of Gynecology and Obstetrics 2009 I-II) endometrial cancer, considering molecular subtypes and new European Society of Gynaecological Oncology (ESGO) risk classification. METHODS: The SENECA study retrospectively reviewed data from 2139 women with stage I-II endometrial cancer across 66 centers in 16 countries. Patients underwent surgery with SLN assessment following ESGO guidelines between January 2021 and December 2022. Molecular analysis was performed on pre-operative biopsies or hysterectomy specimens. RESULTS: Among the 2139 patients, the molecular subgroups were as follows: 272 (12.7%) p53 abnormal (p53abn, 1191 (55.7%) non-specific molecular profile (NSMP), 581 (27.2%) mismatch repair deficient (MMRd), 95 (4.4%) POLE mutated (POLE-mut). Tracer diffusion was detected in, at least one side, in 97.2% of the cases; with a bilateral diffusion observed in 82.7% of the cases. By ultrastaging (90.7% of the cases) or one-step nucleic acid amplification (198 (9.3%) of the cases), 205 patients were identified with affected sentinel lymph nodes, representing 9.6% of the sample. Of these, 139 (67.8%) had low-volume metastases (including micrometastases, 42.9%; and isolated tumor cells, 24.9%) while 66 (32.2%) had macrometastases. Significant differences in SLN involvement were observed between molecular subtypes, with p53abn and MMRd groups having the highest rates (12.50% and 12.40%, respectively) compared with NSMP (7.80%) and POLE-mut (6.30%), (p=0.004); (p53abn, OR=1.69 (95% CI 1.11 to 2.56), p=0.014; MMRd, OR=1.67 (95% CI 1.21 to 2.31), p=0.002). Differences were also noted among ESGO risk groups (2.84% for low-risk patients, 6.62% for intermediate-risk patients, 21.63% for high-intermediate risk patients, and 22.51% for high-risk patients; p<0.001). CONCLUSIONS: Our study reveals significant differences in SLN involvement among patients with early-stage endometrial cancer based on molecular subtypes. This underscores the importance of considering molecular characteristics for accurate staging and optimal management decisions.

© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.

Datos de la publicación

ISSN/ISSNe:
1048-891X, 1525-1438

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER  LIPPINCOTT WILLIAMS & WILKINS

Tipo:
Article
Páginas:
1313-1321
Factor de Impacto:
0,854 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Endometrial Neoplasms; Sentinel Lymph Node

Campos de estudio

Proyectos asociados

Assessment of the prognostic impact of the published European Society of Gynecologic Oncology quality indicators for advanced ovarian cancer surgery.

Investigador Principal: MARTA ARNÁEZ DE LA CRUZ

2023-332-1 . 2023

SENECA Study: Staging Endometrial caNcer based on molEcular ClAssification.

Investigador Principal: MARTA ARNÁEZ DE LA CRUZ

2022.195 . 2023

Validación del ganglio centinela en cáncer de endometrio de alto riesgo prequirúrgico en estadio inicial basado en la clasificación molecular.

Investigador Principal: PABLO PADILLA ISERTE

CEImLAR PI 682 . 2023

Desarrollo de una herramienta de diagnóstico molecular del cáncer de endometrio.

Investigador Principal: MARTA ARNÁEZ DE LA CRUZ

PR(AMI)653/2021 . 2025

Estudio retrospectivo: Técnica de detección de ganglio centinela mediante la utilización de verde de indocianina en el cáncer de ovario en estadio inicial.

Investigador Principal: VÍCTOR LAGO LEAL

SENTOV-ICG . 2024

Análisis económico de la adopción de tecnología médica: Eficiencia de la cirugía oncológica ginecológica robótica comparada con cirugía laparoscópica.

Investigador Principal: VÍCTOR LAGO LEAL

END-COST . 2024

Cita

Compartir